Methoxetamine: Difference between revisions

Line 5:

<ref>MXE Binding profile | http://www.homeoffice.gov.uk/publications/agencies-public-bodies/acmd1/methoxetamine2012?view=Binary</ref>

This ~~substance~~ was originally developed ~~as a [[research chemical]]~~ through the use of intelligent drug design, as a potential treatment for [https://en.wikipedia.org/wiki/Phantom_pain Phantom Limb Syndrome] among other ailments.<ref>Interview with a ketamine chemist | https://www.vice.com/en_us/article/interview-with-ketamine-chemist-704-v18n2</ref>

This compound was originally developed through the use of intelligent drug design, as a potential treatment for [https://en.wikipedia.org/wiki/Phantom_pain Phantom Limb Syndrome] among other ailments.<ref>Interview with a ketamine chemist | https://www.vice.com/en_us/article/interview-with-ketamine-chemist-704-v18n2</ref>

MXE had almost no history of human usage and was first identified by the European Monitoring Centre for Drugs and Drug Addiction, which monitors the Internet for new psychoactive substances within the European Union, in November 2010. By July 2011, they had identified 58 websites selling the compound at the cost of 145–195 euros for 10 grams.<ref>Online sales of new psychoactive substances/‘legal highs’ | http://www.emcdda.europa.eu/attachements.cfm/att_143801_EN_SnapshotSummary.pdf</ref>

@@ Line 5: / Line 5: @@
 <ref>MXE Binding profile | http://www.homeoffice.gov.uk/publications/agencies-public-bodies/acmd1/methoxetamine2012?view=Binary</ref>
-This substance was originally developed as a [[research chemical]] through the use of intelligent drug design, as a potential treatment for [https://en.wikipedia.org/wiki/Phantom_pain Phantom Limb Syndrome] among other ailments.<ref>Interview with a ketamine chemist | https://www.vice.com/en_us/article/interview-with-ketamine-chemist-704-v18n2</ref>
+This compound was originally developed through the use of intelligent drug design, as a potential treatment for [https://en.wikipedia.org/wiki/Phantom_pain Phantom Limb Syndrome] among other ailments.<ref>Interview with a ketamine chemist | https://www.vice.com/en_us/article/interview-with-ketamine-chemist-704-v18n2</ref>
 MXE had almost no history of human usage and was first identified by the European Monitoring Centre for Drugs and Drug Addiction, which monitors the Internet for new psychoactive substances within the European Union, in November 2010. By July 2011, they had identified 58 websites selling the compound at the cost of 145–195 euros for 10 grams.<ref>Online sales of new psychoactive substances/‘legal highs’ | http://www.emcdda.europa.eu/attachements.cfm/att_143801_EN_SnapshotSummary.pdf</ref>